Novartis AG 2023 IR
The report outlines Novartis' transition into a fully focused innovative medicines company following the spin-off of its Sandoz business in 2023. It highlights strong financial performance with net sales of USD 45.4 billion and key product growth, alongside significant R&D investments of USD 8.6 billion. The company achieved its gender balance target with 48% women in management and reduced its own greenhouse gas emissions by 63% compared to a 2016 baseline. Additionally, Novartis implemented global access strategies for all new medicine launches to expand healthcare reach in low- and middle-income countries.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2023
Type: IR
Pages: 101
Back to company
Novartis AG
Integrated Report
The report outlines Novartis' transition into a fully focused innovative medicines company following the spin-off of its Sandoz business in 2023. It highlights strong financial performance with net sales of USD 45.4 billion and key product growth, alongside significant R&D investments of USD 8.6 billion. The company achieved its gender balance target with 48% women in management and reduced its own greenhouse gas emissions by 63% compared to a 2016 baseline. Additionally, Novartis implemented global access strategies for all new medicine launches to expand healthcare reach in low- and middle-income countries.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees